Hester Biosciences Reports Q1 FY27 Results; Consolidated Profit Jumps Following Loan Amendment Gain

Hester Biosciences Reports Q1 FY27 Results; Consolidated Profit Jumps Following Loan Amendment Gain​

Hester Biosciences Limited has announced its unaudited financial results for the first quarter of fiscal year 2027 (Q1 FY27), reflecting significant profitability improvements across both standalone and consolidated operations. The company reported a massive profit jump in the consolidated segment, largely driven by an exceptional gain realized from a loan amendment involving Hester Biosciences Africa Limited.

The Board of Directors approved the results, which highlight strong operational execution and strategic focus areas for the upcoming fiscal year.

Consolidated Financial Highlights Show Substantial Profit Growth​

For the quarter ended 30 June 2026, the Group reported total revenue from operations at INR 772.44 million, up from INR 841.05 million in the corresponding period of FY26. Total income stood at INR 788.87 million.

The consolidated results benefited significantly from a special accounting gain recognized due to a loan modification. The amendment involved Hester Biosciences Africa Limited and the Gates Foundation (USA), reducing an outstanding principal amount from USD 12.0 million to USD 5.0 million, while waiving all accrued interest. This modification, accounted for as the extinguishment of the original liability, resulted in an exceptional gain recorded as INR 853.49 million, which contributed substantially to the consolidated profit after tax (PAT) of INR 967.32 million.

The profitability metrics show a strong upward trend across the group. Consolidated EBITDA grew significantly by 327% compared to FY26.

Standalone Performance Highlights and Divisional Growth​

Focusing on the standalone results for Q1 FY27, the company reported Total income of INR 743.43 million. The firm recorded a PAT of INR 147.11 million, showing robust growth in profitability compared to previous periods.

The standalone performance demonstrated operational efficiency gains, with Gross Profit Margin improving to 78% from 69%. EBITDA and PAT saw marked increases of 95% and 88%, respectively, reflecting disciplined execution across the business units.

Operational Review and Future Strategy​

The company's divisions provided mixed but strategic updates during the quarter.

The Poultry Healthcare Division delivered strong growth, with revenues increasing by 48% over the previous corresponding quarter. This segment's success was attributed to higher institutional business, deepening market penetration, and the introduction of new health products such as feed supplements and disinfectant solutions.

In contrast, the Animal Healthcare Division continues to navigate challenges related to the timing of government-led immunization programs. Management maintained confidence in long-term growth opportunities within preventive animal healthcare.

Looking ahead, Hester Biosciences Limited reaffirmed its commitment to a long-term strategy focused on "Building with Intent." For FY27, the company plans to:

• Strengthen its biologicals portfolio across both Poultry and Animal Healthcare segments.
• Expand market penetration in domestic and export markets.
• Advance Research and Development through continued investment in new products and regulatory submissions.
• Improve manufacturing efficiency and enhance utilization of newly commissioned facilities.

HESTERBIO Stock Price Movement​

As of 11:21 AM, shares of Hester Biosciences Limited are shedding value in live trading, slipping by 3.24% to ₹2416 as investors track its performance. The stock activity registers a traded volume of 27,433 shares while maintaining intraday volatility.